SCHEMBL422080

SCHEMBL422080

CN(C(=O)O)C12CCC(Cn3c1nc(C(=O)NCc1ccc(F)cc1)c(O)c3=O)C2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.50
CYP2C9 P11712 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.38
KCNE1 P15382 1/20 0.38
CCR1 P32246 1/20 0.38
KCNQ1 P51787 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NPSR1 Q6W5P4 2/20 0.36
GAA P10253 1/20 0.36
ERCC1 P07992 1/20 0.36
FEN1 P39748 1/20 0.36
ERCC4 Q92889 1/20 0.36
CALCA P06881 1/20 0.36
LIPG Q9Y5X9 1/20 0.35
THRB P10828 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL52210 0.95 KCNH2 (0.51) KCNH2CYP2C9SMN1; SMN2KCNE1CCR1
SCHEMBL63268 0.93 KCNH2 (0.53) KCNH2CYP2C9SMN1; SMN2KCNE1CCR1
SCHEMBL415591 0.92 CYP2C9 (0.56) KCNH2CYP2C9SMN1; SMN2KCNE1CCR1
SCHEMBL52222 0.90 KCNH2 (0.54) KCNH2CYP2C9SMN1; SMN2KCNE1CCR1
SCHEMBL10144362 0.89 KCNH2 (0.48) KCNH2CYP2C9SMN1; SMN2KCNE1CCR1
SCHEMBL52461 0.87 KCNH2 (0.49) KCNH2CYP2C9SMN1; SMN2KCNE1CCR1
SCHEMBL53197 0.87 CYP2C9 (0.58) KCNH2CYP2C9SMN1; SMN2KCNE1CCR1
SCHEMBL420084 0.87 CYP2C9 (0.48) KCNH2CYP2C9SMN1; SMN2KCNE1CCR1
SCHEMBL418928 0.87 KCNE1 (0.50) KCNH2CYP2C9SMN1; SMN2KCNE1CCR1
SCHEMBL422140 0.86 KCNH2 (0.50) KCNH2CYP2C9SMN1; SMN2KCNE1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS VENKATRAMAN SHANKAR (US) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS CCND3, CDK3, CDK2 KCNH2 2502/4885CYP2C9 1960/4885SMN1; SMN2 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.